KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedCurrent implied probability
Yes 98%
Market quality
45 / 100
Low quality24h Volume
$749.5
Liquidity
$2.2K
Low liquidityBid / Ask
77.0% / 99.0%
Spread
22.0 pt
Wide spreadMarket data
Updated 10 minutes ago
Jun 17, 26, 9:00 PM UTCJan 1, 27, 4:59 AM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Venglustat by Sanofi (in 2026)
KalshiFDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRules
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Settles via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep.
- It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions.
- This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.
Open markets
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Total Vol
- $18.1M
- 24h Vol
- $22.1K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Total Vol
- $1.9M
- 24h Vol
- $6K
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 more outcomes
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Total Vol
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Total Vol
- $1.1M
- 24h Vol
- $1.8K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000-1.0pt96%
- Above 6000+1.0pt60%
+2 more outcomes
- Total Vol
- $1M
- 24h Vol
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
Frequently asked questions
- What are the current odds for FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- Kalshi prices Yes at 98% as of September 8, 2026.
- When does FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) resolve?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) is scheduled to resolve on January 1, 2027.
- How is FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) settled?
- Kalshi settles this market as follows: If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.